Group 1 - The core index of the China Securities Internet Medical Theme Index (CS Internet Medical, 930720) opened lower but rose, closing at 2514.46 points with a trading volume of 6.017 billion yuan [1] - Over the past month, the CS Internet Medical Theme Index has decreased by 12.73%, increased by 15.90% over the past three months, and has risen by 5.70% year-to-date [1] - The index reflects the overall performance of representative companies providing hardware, software, or services for medical informationization and intelligence [1] Group 2 - The top ten weighted companies in the CS Internet Medical Theme Index are: Yifeng Pharmacy (6.65%), Daclin (6.44%), Laobaixing (6.21%), Wandong Medical (5.53%), Haier Biomedical (5.48%), Jiuzhoutong (5.44%), Yixintang (5.37%), Aier Eye Hospital (5.33%), Yuyue Medical (5.28%), and Lepu Medical (5.17%) [1] - The market share of the CS Internet Medical Theme Index holdings is 51.03% from the Shenzhen Stock Exchange and 48.97% from the Shanghai Stock Exchange [1] - The industry composition of the index holdings shows that 70.41% is in pharmaceuticals and healthcare, 25.78% in information technology, and 3.81% in communication services [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day after the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] Group 4 - Public funds tracking the CS Internet Medical Index include: Huatai-PineBridge China Securities Internet Medical A and Huatai-PineBridge China Securities Internet Medical C [3]

Core Insights - The report highlights the performance of the Hong Kong stock market, with the Hang Seng Index at 20,682, reflecting a 2.1% increase year-to-date [3]. - The report indicates that the market is currently influenced by geopolitical tensions, particularly between the US and China, which has led to increased volatility and a rise in gold prices [11][12]. - The report notes that the recent performance of specific stocks within the Hang Seng Index shows significant variances, with JD Health (6618) leading with an 8.2% daily increase and a 15.7% year-to-date increase [4]. Market Overview - The Hang Seng Index has seen a trading volume of HKD 3,955.3 billion, with a price-to-earnings (PE) ratio of 9.2 and a price-to-book (PB) ratio of 0.98 [5]. - The H-share index recorded a trading volume of HKD 1,659.8 billion, with a PE ratio of 8.6 and a PB ratio of 0.91 [5]. - The technology index had a trading volume of HKD 1,283.1 billion, with a PE ratio of 19.8 and a PB ratio of 2.70 [5]. Stock Performance - The report identifies the top three performing stocks in the Hang Seng Index: JD Health (6618) with a price of HKD 32.50, Lenovo Group (0992) at HKD 8.03, and BYD Electronics (0285) at HKD 31.05 [4]. - Conversely, the worst performers include China Shenhua (1088) at HKD 30.35, New Oriental Education (9901) at HKD 33.60, and Xinao Gas (2688) at HKD 60.00 [4]. Economic Indicators - The report mentions that the People's Bank of China maintained the 5-year Loan Prime Rate (LPR) at 3.60% and the 1-year LPR at 3.10% [11]. - The US Federal Reserve decided to keep interest rates unchanged in March, with expectations of two rate cuts totaling 0.5% later in the year [11]. - The report also highlights the recent inflation data from the US, with the March Consumer Price Index (CPI) at 2.4%, below the expected 2.5% [15]. Company Analysis - The report discusses the strong performance of Zhaojin Mining (1818.HK), which reported a revenue increase of 37.12% year-on-year to RMB 11.55 billion, with a net profit increase of 112% to RMB 1.45 billion [26]. - The company achieved a total gold production of 26,449.73 kg, a year-on-year increase of 7.15%, driven by acquisitions and increased processing capacity [26][27]. - The report notes that Zhaojin Mining's current price of HKD 15.06 reflects a trailing twelve months (TTM) PE ratio of approximately 33.69, which is lower than the 10-year average of 60.65, indicating an attractive valuation [27].

Core Viewpoint - The article highlights the importance of comprehensive management for constipation and digestive system diseases, emphasizing the role of JD Health in providing accessible and professional health services for patients [1][2][4]. Group 1: Disease Prevalence and Impact - Constipation affects 4% to 6% of adults in China, with the prevalence increasing with age, reaching up to 22% in individuals over 60 years old [2]. - Long-term constipation can lead to serious health issues, including abdominal pain, anal diseases, and cardiovascular problems [2]. Group 2: Comprehensive Health Services - JD Health advocates for a full-cycle management approach for constipation, offering services from prevention and diagnosis to treatment and rehabilitation [2]. - The platform provides extensive educational content on symptoms, causes, prevention, and treatment of digestive system diseases, presented in an easy-to-understand format [2]. Group 3: Diagnostic and Treatment Support - JD Health integrates online and offline resources to facilitate convenient online consultations with top digestive specialists from renowned medical institutions [2]. - The company offers a wide range of medications and personalized medication guidance from professional pharmacists, ensuring safe and effective treatment [3]. Group 4: Long-term Health Management - JD Health employs big data analysis to provide personalized health assessments and management recommendations, including dietary adjustments and exercise plans [3]. - The company collaborates with offline pharmacies and medical institutions to create a comprehensive healthcare network, enhancing service accessibility and efficiency [3]. Group 5: Future Directions - JD Health aims to continue innovating service models to provide more professional, convenient, and efficient health services for constipation patients, while promoting standardized diagnosis and management of digestive system diseases [4].

As filed with the Securities and Exchange Commission on March 31, 2025 Registration No. 333-285771 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ AMENDMENT NO. 1 TO FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 __________________________ POMDOCTOR LIMITED (Exact name of Registrant as specified in its charter) __________________________ Not Applicable (Translation of Registrant's name into English) __________________________ | Cayman Islands | 7389 | N ...

Core Insights - The company, Ark Health, reported a total revenue of 2.707 billion yuan for 2024, marking an 11.2% year-on-year increase, and an adjusted net profit of 17.119 million yuan, which is a 139% increase compared to 2023, showcasing its enhanced profitability and the effectiveness of AI in the healthcare sector [3][4] - Ark Health focuses on internet-based chronic disease management, providing comprehensive services and has successfully listed on the Hong Kong Stock Exchange, boosting market confidence in the internet and pharmaceutical industries [3][4] - The company aims to maintain high-quality development by leveraging AI technology and innovation, particularly in the Guangdong-Hong Kong-Macao Greater Bay Area [3][4] Financial Performance - Online retail pharmacy services contributed 1.405 billion yuan in revenue, up 8.3%, while customized content and marketing solutions generated 105 million yuan, with a growth rate of 20.7% [4] - The gross margin for comprehensive medical services improved from 15.20% at the end of 2023 to 17.20% at the end of 2024, indicating a focus on sustainable business development [4] - The registered user base for the chronic disease management service platform grew from 42.7 million to 49.2 million, with a monthly active user count rising to 10.1 million, reflecting a 20% year-on-year increase [4][5] Technological Advancements - The company has integrated advanced technologies such as large language models, big data, and cloud computing to enhance its service offerings, including AI doctor assistants and AI customer service assistants [6][7] - The AI doctor assistant can handle over 80% of repetitive inquiries, allowing doctors to focus on complex cases, thereby improving service efficiency and reducing costs [6][7] - The integration of the DeepSeek model and proprietary technology has created a closed-loop service system from hospitals to homes, enhancing the overall healthcare value chain [6][7] Market Position and Strategy - Ark Health has established partnerships with over 1,500 suppliers and 900 pharmaceutical companies, offering approximately 215,000 drug SKUs, with 62% being prescription drugs [4][5] - The company is positioned to strengthen its leading market position in online chronic disease management through strategic initiatives and continuous optimization of its operational tactics [5][6] - The integration of its service platform with medical insurance payment systems has improved user retention and reduced financial burdens on patients, further solidifying its market position [8][9] Industry Impact - The recent inclusion of Ark Health in the Hong Kong Stock Connect is expected to attract more mainland investors, potentially enhancing liquidity and valuation [8] - The company's growth reflects its competitive strength in the internet healthcare sector and contributes to the high-quality development of the biopharmaceutical industry in Guangdong [9] - The supportive policies from the National Health Commission regarding AI applications in healthcare signal a positive outlook for the internet healthcare industry, encouraging further innovation [9]

将投中网设为"星标⭐"，第一时间收获最新推送 估值超过200亿元。 来源丨投中网 一家来自广州的明星独角兽，来到纳斯达克门前。 近日，石榴云医申请在美上市。在创始人石振洋的带领下，这家专注于慢性病管理和医药服务的公司，签约超过20万名医生， 并开出超过300万张处方，同时服务的患者也增加到68.3万名。 这番成绩背后，离不开众多投资者的支持。 一路走来，在拿到红杉中国、京东、景林投资、邦盛资本、长江国弘、天亿集团（中卫基金）、东方证券、力合股份、分享投 资、清控银杏、高特佳投资、分众传媒、步长制药等投资后，石榴云医的估值超过200亿元。 医生创业，广州冲出一家明星公司 作者丨鲁智高 家人的看病经历，最终让石振洋走上创业之路。 从母亲患病得不到有效治疗，到表弟生病却被乡里医生误诊，原本打算长期做医生的他意识到，仅凭一人之力去救死扶伤很难 彻底改善原有的医疗状况。 于是，石振洋决定弃医从商，并在2001年来到广州创业。带着几千块钱，他选择从药品代理做起，并成功于2005年成立了自己 的第一家药房——七乐康。四年后，他已经拥有七家药房，每天的现金流也达到数万元。 判断医药电商拥有巨大的发展潜力后，石振洋果断申报互联 ...

Core Viewpoint - JD Health is leveraging AI to enhance medical health services, focusing on high-quality development through AI-driven solutions in health management and patient care [1][2]. Group 1: AI in Healthcare - AI is recognized as a new production factor that should address deep-rooted issues across various industries, particularly in healthcare [2]. - JD Health's "Jingyi Qianxun" medical model has been fully open-sourced, making it the first vertical model in the domestic healthcare sector to do so, which will lower the development barriers for medical AI applications [2][3]. - The AI diagnosis assistant 2.0 boasts a triage accuracy rate of 99.5%, with a 120% increase in electronic medical record writing efficiency and over 90% problem-solving rate [3]. Group 2: AI Products and Services - JD Health has launched several AI-driven services, including the intelligent health assistant "Kangkang" and the AI psychological companion "Therapeutic Little Universe," creating an online medical service ecosystem [3]. - The AI doctor digital entity is designed to provide 24/7 responses to patient inquiries, enhancing the efficiency of medical services [3]. Group 3: Data Security and Privacy - The company emphasizes that AI models learn from de-identified "knowledge data" rather than clinical data, addressing data security and privacy concerns [3]. - Patients are informed about the use of their data, allowing them to choose between protecting or sharing their information [3]. Group 4: Future Directions - JD Health aims to continuously explore the potential of AI in healthcare, focusing on technological innovation to build a safer, more efficient, and convenient medical service system [4].

Core Viewpoint - Ant Group, in collaboration with Huawei and Alibaba Cloud, has launched a comprehensive AI solution for hospitals, marking a significant step in the application of AI in the medical field, integrating AI capabilities across institutions, doctors, and patients [1][4][15] Group 1: AI Model and Medical Service Upgrade - The introduction of large models is driving an upgrade in medical services, with significant breakthroughs in technology lowering the barriers for AI in healthcare [2][3] - Major players like Huawei, Tencent, and Ant Group are entering the medical AI space, indicating a competitive landscape for AI applications in healthcare [4][15] Group 2: Ant Group's Unique Approach - Ant Group has a long history of involvement in digital healthcare, having established a strong foundation over 11 years, which positions it well for the integration of AI in medical services [7][10] - The company has developed a "three-in-one" strategy that integrates AI applications for institutions, doctors, and patients, enhancing the overall healthcare ecosystem [5][6][15] Group 3: AI Product Offerings - Ant Group has launched various AI tools for different stakeholders: a full-stack AI solution for hospitals, AI assistant tools for doctors, and an "AI Health Manager" for patients [5][6][14] - The AI Health Manager has already served nearly 30 million users across over 1,000 medical institutions in Zhejiang Province [14] Group 4: Future Prospects and Industry Impact - The integration of AI in healthcare is expected to significantly improve resource utilization and reduce costs, with predictions indicating a potential saving of over $1.2 trillion globally by 2030 [15] - Ant Group's model of open technology and collaboration with nearly 100 partners is seen as a practical example for the scalable implementation of medical AI [15]

Core Viewpoint - Dingdang Health has been unprofitable since its listing nearly three years ago, with significant losses continuing into 2024, raising concerns about goodwill impairment and overall financial health [2][5][11]. Financial Performance - In 2024, Dingdang Health reported total revenue of 4.669 billion yuan, a year-on-year decrease of 3.87% [2][5]. - The company experienced a shareholder loss of 376 million yuan in 2024, which represents a year-on-year increase of 66.73% [2][5]. - Cumulative losses over three years have reached approximately 3.435 billion yuan [5]. Goodwill Impairment - Dingdang Health recognized a goodwill impairment loss of approximately 199 million yuan and an additional intangible asset impairment loss of 6.8 million yuan for the fiscal year 2024 [2][6]. - Specific impairments related to acquisitions of various pharmacies were detailed, with significant losses attributed to the acquisition of the Renhe Pharmacy Network and others [6]. Market Strategy and Competition - The company has adjusted its strategy by pausing operations in non-core cities like Chongqing and Nanjing, focusing instead on major markets such as Beijing, Shanghai, and Shenzhen [5][9]. - Increased competition in the online healthcare market has pressured Dingdang Health's market share and revenue growth, as traditional retail and e-commerce giants enter the instant delivery space [9]. Cost Structure - Dingdang Health's cost structure remains a significant factor in its ongoing losses, with fulfillment and marketing expenses comprising a large portion of total costs [10]. - In 2023, fulfillment expenses increased by 10.8% to 492 million yuan, while marketing expenses rose by 7.1% to 973 million yuan [10]. Stock Market Performance - Since its IPO, Dingdang Health's stock has seen a dramatic decline, with its market capitalization dropping over 95% from its peak [10][12]. - The stock price fell from an initial offering price of 12 HKD per share to approximately 0.5 HKD per share by March 2023, resulting in a market cap of about 660 million HKD [11][12]. Comparison with Peers - Other listed internet healthcare companies such as JD Health, Alibaba Health, and Ping An Good Doctor have shown better fundamentals, with some achieving profitability in recent fiscal years [13].

Group 1 - Ark Health (06086) saw a significant stock increase of over 17%, currently trading at 5.77 HKD with a transaction volume of 138 million HKD [1] - The company recently announced the integration of DeepSeek's open-source large model, completing private deployment, which enhances the digital drive for "AI + chronic disease management" [1][2] - Ark Health aims to develop multiple "AI intelligent assistant" scenarios by 2025, increasing R&D investment to leverage advanced models like DeepSeek for extracting medical data value [2] Group 2 - The launch of the first fully domestic intelligent solution in the medical industry, "Bianshi + DeepSeek dual-engine medical intelligent machine," was a collaborative effort with Huawei [1] - The company is focusing on creating a "H2H (Hospital To Home) smart medical ecosystem" to upgrade its "AI + H2H" strategy, positioning it as a new growth point for its smart medical business [1] - Ark Health has recently been included in the Hong Kong Stock Connect list and is set to release its 2024 annual performance report [2]